Taysha Gene Therapies Inc (TSHA)

$4.88 +0.13 (2.74%)
Market Cap 1.30B
Revenue (ttm) 8.33M
Net Income (ttm) -89.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,072.03%
Debt to Equity Ratio 0.17
Volume 2,084,980
Avg Vol 6,968,804
Day's Range N/A - N/A
Shares Out 272.80M
Stochastic %K 30%
Beta 0.99
Analysts Strong Sell
Price Target $9.77

Company Profile

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for t...

Industry: Biotechnology
Sector: Healthcare
Phone: 214 612 0000
Address:
3000 Pegasus Park Drive, Suite 1430, Dallas, United States
Dark_Horse_Investments
Dark_Horse_Investments Oct. 27 at 6:57 PM
$TSHA choppy seesaw reaction the last ~two weeks ... Do we think this will end the year above $6 ? THX & good luck
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 26 at 5:16 PM
Nice to see RA Capital long 7m shares of $RNA. A cool $1/2b that needs re-investing tomorrow thanks to $NVS. They are some lucky investors - or . *are they the actual people who facilitate value creation*? https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline $IFRX $CDTX $TSHA
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 5:43 PM
Raymond James has updated their rating for Taysha Gene Therapies ( $TSHA ) to Strong Buy with a price target of 13.
1 · Reply
King_of_Bio
King_of_Bio Oct. 21 at 3:22 PM
$TSHA She's headed for the next leg up!
1 · Reply
DaBullRunner
DaBullRunner Oct. 20 at 10:40 PM
$ABAT what a comeback 💪🤑💰💰💰💰 RVP is my next one 🚨🚨🚨 Here’s why👇 $BYND $TSHA what an AH
0 · Reply
Quantumup
Quantumup Oct. 20 at 8:30 PM
Raymond James🏁 $TSHA Strong Buy/$13 $NGNE $ACAD $ALPMY Raymond James said: Initiating coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target, as we think TSHA is well-positioned for success in its pivotal trial for patients with Rett syndrome (RTT), based on strong results from Part A of the Phase 1/2 REVEAL trial and constructive feedback from FDA. Raymond James added:
0 · Reply
biotech
biotech Oct. 20 at 5:37 PM
$SGMO $TSHA $QURE
1 · Reply
quickaspeter
quickaspeter Oct. 19 at 11:30 PM
$TSHA “Taysha Gene Therapies regained full rights to its TSHA-102 gene therapy program for Rett syndrome after the expiration of an agreement with Astellas. This change restores their strategic flexibility at the same time the therapy received FDA Breakthrough Therapy status.” https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-valuation-perspectives-after-rega
0 · Reply
Mighty_Fire_5931
Mighty_Fire_5931 Oct. 19 at 10:11 PM
$TSHA Perfect bounce off support, adding here
0 · Reply
Dkll303
Dkll303 Oct. 18 at 1:04 PM
$QURE $SGMO $TSHA cantor is the world's worst at very thing they touch , including but not limited to 1) how. Tariffs are legally initiated, lol 2) who pays for Lutnick’s illegal idea of tariffs No more needed to be said …Low , scum , investment house
1 · Reply
Latest News on TSHA
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

Oct 16, 2025, 4:01 PM EDT - 11 days ago

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting

Oct 9, 2025, 8:00 AM EDT - 18 days ago

Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting

Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential

Oct 6, 2025, 10:07 AM EDT - 21 days ago

Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 4:05 PM EDT - 24 days ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome

Oct 2, 2025, 8:00 AM EDT - 25 days ago

Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome

Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 1:38 PM EDT - 2 months ago

Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 8:01 AM EDT - 2 months ago

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12

Aug 5, 2025, 4:05 PM EDT - 2 months ago

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

Jun 3, 2025, 5:17 PM EDT - 5 months ago

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

May 29, 2025, 1:06 PM EDT - 5 months ago

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

May 28, 2025, 10:40 PM EDT - 5 months ago

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 28, 2025, 4:02 PM EDT - 5 months ago

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

May 28, 2025, 4:01 PM EDT - 5 months ago

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript

May 15, 2025, 2:07 PM EDT - 5 months ago

Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript

Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 5 months ago

Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

May 8, 2025, 4:05 PM EDT - 6 months ago

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Mar 31, 2025, 2:25 PM EDT - 7 months ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SLDB SRPT XBI

Taysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 2:54 PM EST - 8 months ago

Taysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call Transcript

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

Feb 26, 2025, 8:00 AM EST - 8 months ago

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

Feb 19, 2025, 8:00 AM EST - 8 months ago

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

Taysha Gene Therapies Is Showing Promise For Rett Syndrome

Jan 27, 2025, 7:53 PM EST - 9 months ago

Taysha Gene Therapies Is Showing Promise For Rett Syndrome

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Nov 14, 2024, 8:25 AM EST - 1 year ago

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

AAP

Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 10:48 PM EST - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:01 PM EST - 1 year ago

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Oct 14, 2024, 12:55 AM EDT - 1 year ago

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 12:08 PM EDT - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 8:01 AM EDT - 1 year ago

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Jun 26, 2024, 7:36 AM EDT - 1 year ago

Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

GIS

What's Going On With Taysha Gene Therapies Stock Tuesday?

Jun 18, 2024, 11:42 AM EDT - 1 year ago

What's Going On With Taysha Gene Therapies Stock Tuesday?

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Jun 18, 2024, 7:30 AM EDT - 1 year ago

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:55 AM EDT - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:01 PM EDT - 1 year ago

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

May 7, 2024, 4:05 PM EDT - 1 year ago

Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

May 2, 2024, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Mar 20, 2024, 12:30 PM EDT - 1 year ago

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 9:04 PM EDT - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Mar 19, 2024, 4:01 PM EDT - 1 year ago

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19

Mar 14, 2024, 4:26 PM EDT - 1 year ago

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

Feb 29, 2024, 8:00 AM EST - 1 year ago

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Feb 15, 2024, 4:01 PM EST - 1 year ago

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

Jan 22, 2024, 8:00 AM EST - 1 year ago

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Jan 10, 2024, 8:00 AM EST - 1 year ago

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies

Dec 19, 2023, 7:30 AM EST - 2 years ago

Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies

TRIN

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Nov 29, 2023, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Taysha Gene Therapies, Inc. (TSHA) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 9:53 PM EST - 2 years ago

Taysha Gene Therapies, Inc. (TSHA) Q3 2023 Earnings Call Transcript

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Nov 14, 2023, 4:08 PM EST - 2 years ago

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14

Nov 7, 2023, 8:00 AM EST - 2 years ago

Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14

Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'

Nov 3, 2023, 7:41 PM EDT - 2 years ago

Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'

Dark_Horse_Investments
Dark_Horse_Investments Oct. 27 at 6:57 PM
$TSHA choppy seesaw reaction the last ~two weeks ... Do we think this will end the year above $6 ? THX & good luck
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 26 at 5:16 PM
Nice to see RA Capital long 7m shares of $RNA. A cool $1/2b that needs re-investing tomorrow thanks to $NVS. They are some lucky investors - or . *are they the actual people who facilitate value creation*? https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline $IFRX $CDTX $TSHA
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 5:43 PM
Raymond James has updated their rating for Taysha Gene Therapies ( $TSHA ) to Strong Buy with a price target of 13.
1 · Reply
King_of_Bio
King_of_Bio Oct. 21 at 3:22 PM
$TSHA She's headed for the next leg up!
1 · Reply
DaBullRunner
DaBullRunner Oct. 20 at 10:40 PM
$ABAT what a comeback 💪🤑💰💰💰💰 RVP is my next one 🚨🚨🚨 Here’s why👇 $BYND $TSHA what an AH
0 · Reply
Quantumup
Quantumup Oct. 20 at 8:30 PM
Raymond James🏁 $TSHA Strong Buy/$13 $NGNE $ACAD $ALPMY Raymond James said: Initiating coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target, as we think TSHA is well-positioned for success in its pivotal trial for patients with Rett syndrome (RTT), based on strong results from Part A of the Phase 1/2 REVEAL trial and constructive feedback from FDA. Raymond James added:
0 · Reply
biotech
biotech Oct. 20 at 5:37 PM
$SGMO $TSHA $QURE
1 · Reply
quickaspeter
quickaspeter Oct. 19 at 11:30 PM
$TSHA “Taysha Gene Therapies regained full rights to its TSHA-102 gene therapy program for Rett syndrome after the expiration of an agreement with Astellas. This change restores their strategic flexibility at the same time the therapy received FDA Breakthrough Therapy status.” https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-valuation-perspectives-after-rega
0 · Reply
Mighty_Fire_5931
Mighty_Fire_5931 Oct. 19 at 10:11 PM
$TSHA Perfect bounce off support, adding here
0 · Reply
Dkll303
Dkll303 Oct. 18 at 1:04 PM
$QURE $SGMO $TSHA cantor is the world's worst at very thing they touch , including but not limited to 1) how. Tariffs are legally initiated, lol 2) who pays for Lutnick’s illegal idea of tariffs No more needed to be said …Low , scum , investment house
1 · Reply
biotech
biotech Oct. 18 at 11:56 AM
$SGMO Cantor says $TSHA roughly 1/3 $QURE market cap despite both: latestage derisking data regulatory support both sizable rare disease markets $QURE ~5-6K patients vs ~10K patients for $TSHA i say same goes for $SGMO but with 25K+ Fabry patients $SGMO marketcap 190M or 1/17 $QURE
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Oct. 17 at 9:49 PM
seems $NGNE was more dependent on the Astellas exclusive rights to acquire RETT asset (company) from $TSHA than tsha was to hold price level As astellas exclusivity expired on ~ 09/30/25, as confirmed yesterday by TSHA sec filing, both companies traded down today (logically TSHA was expected to face trading pressure) notwithstanding TSHA down -7% NGNE down -14.5% where is the fluff valuation ?
0 · Reply
warren5677
warren5677 Oct. 17 at 7:54 PM
$TSHA Close of $4.75 or better is what I was thinking all day. It's going to be close.
0 · Reply
biotech
biotech Oct. 17 at 3:54 PM
$SGMO $TSHA #Astellas
1 · Reply
JFais
JFais Oct. 17 at 2:23 PM
Gene therapy players in Rett $NGNE $TSHA at top of losers scan today
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 11:58 AM
Chardan Capital updates rating for Taysha Gene Therapies ( $TSHA ) to Buy, target set at 12.
0 · Reply
biotech
biotech Oct. 17 at 10:44 AM
#Astellas not buying $TSHA re but $SGMO ?
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 10:37 AM
Needham has adjusted their stance on Taysha Gene Therapies ( $TSHA ), setting the rating to Buy with a target price of 10.
0 · Reply
biotech
biotech Oct. 17 at 7:47 AM
$SGMO #Astellas returns right to $TSHA #RETT Syndrome programe ... (intrathecally delivered AAV9) re $SGMO STAC-BBB #RETT $TSHA - Astellas + $SGMO RETT Wedbush: STAC-BBB Neuro Capsids Wedbush $SGMO STAC-BBB Capsid Could Attract Attention from Potential Partners Huntington's, Parkinson's, #Rett #Syndrome, Friedrich's Ataxia, cerebellar ataxias, prion disease, Dravet Syndrome, Alzheimer's, MS, frontotemporal dementia, ALS and progressive supranuclear palsy
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Oct. 16 at 9:13 PM
$TSHA BREAKING NEWS "Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome" * sec filing link below Astellas optionality to acquire Rett program (or perhaps company) is off the table for now... Good for TSHA all around to regain rights for a therapy that works. Will simplify negotiations with potential suitors in the future. ... hummm, is something in the works? https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319512492&type=PDF&symbol=TSHA&cdn=b55420705119565484baa3f482704454&companyName=Taysha+Gene+Therapies+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2025-10-16
1 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Oct. 15 at 6:06 PM
$TSHA Unscientific Poll Here: what is the max peak value of this stock in the next 24 Months: a) $18.5 -> takeout @ $5 Billion b) $24.1 -> max valuation in period, $6.5 Billion c) $12.9 -> early takeout @ $3.5 Billion d) $8.0 -> marred by delays & fda issues e) something different Kindly offer some substantive thoughts, not just like/hearts (all good too but please share) Best to all longs here on this relatively under the radar ride...
2 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Oct. 15 at 5:57 PM
$TSHA Xpekt big institutional buys when the next 13-f are filed...
0 · Reply